GHRH receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-07-14 and is reviewed periodically as new material appears.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
== Ecology == Xanthoria parietina demonstrates a range of physiological and morphological adaptations that facilitate its survival in diverse habitats. Populations in drier, more exposed habitats produce longer-chain surface hydrocarbons (alkanes), whereas those in more humid, cooler regions synthesize shorter-chain alkanes—a response that helps reduce water loss, similar to adaptations seen in vascular plants. Its thallus morphology is plastic; forms in moist stream beds tend to be semi-erect and orange-yellow, whereas those in drier, sun-exposed sites are more compact and darker orange. These differences appear to be induced by environment conditions rather than genetic differences.
30 August – Nicky Gavron, 82, British politician, deputy mayor of London (2000–2003, 2004–2008). 3 September – Flora Fraser, 21st Lady Saltoun, 93, Scottish peer, member of the House of Lords (1979–2014). 18 September – Malcolm Mitchell-Thomson, 3rd Baron Selsdon, 86, British peer, banker and businessman, member of the House of Lords (1963–2021). 1 October – Michael Ancram, 13th Marquess of Lothian, 79, British politician and peer, three-times MP, member of the House of Lords (since 2010). 2 October – Herman Ouseley, Baron Ouseley, 79, Guyanese-born British civil rights activist and politician, member of the House of Lords (2001–2019). 4 October – Alexander Leitch, Baron Leitch, 76, British businessman and life peer, member of the House of Lords (since 2004). 7 October – Hugh Cholmondeley, 5th Baron Delamere, 90, British peer, member of the House of Lords (1979–1999). 12 October – Alex Salmond, 69, Scottish politician, first minister (2007–2014). 20 October – Paul White, Baron Hanningfield, 84, British politician and life peer, member of the House of Lords (since 1998). 4 November – Robin Renwick, Baron Renwick of Clifton, 86, British diplomat and life peer, ambassador to the United States (1991–1995). 6 November – Anna Lo, 74, Northern Irish politician, MLA (2007–2016). Sir John Nott, 92, British politician, MP (1966–1983) and defence secretary (1981–1983). 20 November – John Prescott, Baron Prescott, 86, British politician, deputy prime minister (1997–2007), first secretary of state (2001–2007), and MP (1970–2010).
Adenylyl-sulfate reductase (glutathione) (EC 1.8.4.9) is an enzyme that catalyzes the chemical reaction AMP + sulfite + glutathione disulfide ⇌ {\displaystyle \rightleftharpoons } adenylyl sulfate + 2 glutathione The 3 substrates of this enzyme are adenosine monophosphate, sulfite, and glutathione disulfide, whereas its two products are adenylyl sulfate and glutathione. This enzyme belongs to the family of oxidoreductases, specifically those acting on a sulfur group of donors with a disulfide as acceptor. The systematic name of this enzyme class is AMP,sulfite:glutathione-disulfide oxidoreductase (adenosine-5'-phosphosulfate-forming). Other names in common use include 5'-adenylylsulfate reductase (also used for, internal_xref(ec_num(1,8,99,2))), AMP,sulfite:oxidized-glutathione oxidoreductase, (adenosine-5'-phosphosulfate-forming), and plant-type 5'-adenylylsulfate reductase. In plants, APS is reduced by the plastidic enzyme APS reductase (APR; EC 1.8.4.9) in the presence of physiological concentrations of reduced glutathione (GSH), which acts as an electron donor.
CLE peptides (CLAVATA3/Embryo Surrounding Region-Related) are a group of peptides found in plants that are involved with cell signaling. Production is controlled by the CLE genes. Upon binding to a CLE peptide receptor in another cell, a chain reaction of events occurs, which can lead to various physiological and developmental processes. This signaling pathway is conserved in diverse land plants.
Sources: en.wikipedia.org
4-Aminosalicylic acid, also known as para-aminosalicylic acid (PAS) and sold under the brand name Paser among others, is an antibiotic primarily used to treat tuberculosis. Specifically it is used to treat active drug resistant tuberculosis together with other antituberculosis medications. It has also been used as a second line agent to sulfasalazine in people with inflammatory bowel disease such as ulcerative colitis and Crohn's disease. It is typically taken by mouth. Common side effects include nausea, abdominal pain, and diarrhea. Other side effects may include liver inflammation and allergic reactions. It is not recommended in people with end stage kidney disease. While there does not appear to be harm with use during pregnancy it has not been well studied in this population. 4-Aminosalicylic acid is believed to work by blocking the ability of bacteria to make folic acid. 4-Aminosalicylic acid was first made in 1902, and came into medical use in 1943. It is on the World Health Organization's List of Essential Medicines.
=== Stable isotopes === Stable lutetium can be used as catalysts in petroleum cracking in refineries and can also be used in alkylation, hydrogenation, and polymerization applications. Lutetium aluminium garnet (Al5Lu3O12) has been proposed for use as a lens material in high refractive index immersion lithography. Additionally, a tiny amount of lutetium is added as a dopant to gadolinium gallium garnet, which was used in magnetic bubble memory devices. Cerium-doped lutetium oxyorthosilicate is currently the preferred compound for detectors in positron emission tomography (PET). Lutetium aluminium garnet (LuAG) is used as a phosphor in light-emitting diode light bulbs. Lutetium tantalate (LuTaO4) is the densest known stable white material (density 9.81 g/cm3) and therefore is an ideal host for X-ray phosphors. The only denser white material is thorium dioxide, with density of 10 g/cm3, but the thorium it contains is radioactive. Lutetium is also a compound of several scintillating materials, which convert X-rays to visible light. It is part of LYSO, LuAG and lutetium iodide scintillators. Research indicates that lutetium-ion atomic clocks could provide greater accuracy than any existing atomic clock.
Insulin icodec/semaglutide is an experimental fixed-dose combination of insulin icodec and semaglutide in development for type 2 diabetes by Novo Nordisk. The combination contains insulin icodec, a basal insulin analog; and semaglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist. Insulin icodec regulates glucose metabolism by binding to insulin receptors. Semaglutide regulates insulin and glucagon secretion in a glucose-dependent manner by selectively binding to and activating the GLP-1 receptor, the target for native GLP-1.
===== Laurasiatheria ===== Order Artiodactyla (even-toed ungulates) Family Antilocapridae Antilocapra americana, pronghorn (2019) Family Balaenidae Balaena mysticetus, bowhead whale (2015) Eubalaena glacialis, North Atlantic right whale (2018) Family Balaenopteridae Balaenoptera acutorostrata, common minke whale (2014) Balaenoptera borealis, sei whale (2018) Balaenoptera musculus, blue whale (2018) Balaenoptera physalus, fin whale (2014) Megaptera novaeangliae, humpback whale (2018) Family Bovidae Ammotragus lervia, Barbary sheep (2019) Antidorcas marsupialis, Springbox (2019) Bison bonasus, European bison (2017) Bos grunniens, yak 2012 () Bos primigenius indicus, zebu or Brahman cattle (2012) Bos primigenius taurus, cow 2009 () Bubalus bubalis, river buffalo (2017) Budorcas taxicolor, Takin (2023) Capra ibex, Goats (2019) Cephalophus harveyi, Harvey's duiker (2019) Connochaetes taurinus, blue wildebeest (2019) Damaliscus lunatus, common tsessebe (2019) Gazella thomsoni, Thomson's gazelle (2019) Hippotragus niger, Sable Antelope (2019) Kobus ellipsiprymnus, Waterbuck (2019) Litocranius walleri, Gerenuk (2019) Oreotragus oreotragus, Klipspringer (2019) Oryx gazella, Gemsbok (2019) Ourebia ourebi, Oribi (2019) Ovis ammon, Argali (2019) Ovis ammon polii, marco polo sheep (2017) Nanger granti, Grant's gazelle (2019) Neotragus moschatus, Suni (2019) Neotragus pygmaeus, Royal antelope (2019) Philantomba maxwellii, Maxwell's duiker (2019) Procapra przewalskii, Przewalski's gazelle (2019) Pseudois nayaur, Bharal (2019) Pseudoryx nghetinhensis, Saola (2025) Raphicerus campestris, Steenbox (2019) Redunca redunca, Bohor reedbuck (2019) Syncerus caffer, African buffalo (2019) Sylvicapra grimmia, common duiker (2019) Tragelaphus, Spiral-horned bovine (2019) Tragelaphus buxtoni, Mountain nyala (2019) Tragelaphus strepsiceros, Greater kudu (2019) Tragelaphus imberbis, Lesser kudu (2019) Tragelaphus spekii, Sitatunga (2019) Tragelaphus scriptus, Bushbuck (2019) Taurotragus oryx, Common eland (2019) Family Camelidae Camelus ferus, Wild Bactrian camel (2007) Family Cervidae Cervus albirostris, Tharold's deer (2019) Elaphurus davidianus, Père David's deer (2018) Muntiacus crinifrons, hairy-fronted muntjac (2019) Muntiacus muntjak, Indian muntjac (2019) Muntiacus reevesi, Reeves's muntjac (2019) Odocoileus hemionus, mule deer (2021) Rangifer tarandus, Reindeer (2017) Rusa alfredi, Visayan spotted deer (2025) Family Delphinidae Tursiops truncatus, bottlenosed dolphin (2012) Neophocaena phocaenoides, finless porpoise (2014) Orcinus orca, killer whale (2015) Sousa chinensis, Indo-Pacific humpback dolphin (2019) Family Eschrichtiidae Eschrichtius robustus, gray whale (2018) Family Giraffidae Giraffa camelopardalis, Giraffe (2019) Giraffa camelopardalis tippelskirchi, Masai giraffe (2019) Okapia johnstoni, Okapi (2019) Family Monodontidae Delphinapterus, beluga whale (2017) Family Moschidae Moschus berezovskii, forest musk deer (2018) Moschus chrysogaster, Alpine musk deer (2019) Family Phocoenidae Neophocaena asiaeorientalis sunameri, East Asian finless porpoise (2024) Neophocaena asiaorientalis asiaorientalis, Yangtze finless porpoise (2024) Family Physeteridae Physeter macrocephalus, sperm whale (2019) Family Suidae Sus scrofa, pig (2012) Family Tragulidae Tragulus javanicus, Java mouse-deer (2019) Order Carnivora Family Felidae Acinonyx jubatus, cheetah (2015) Felis catus, cat (2007) Panthera leo, lion (2013) Panthera pardus, Amur leopard (2016) Panthera tigris tigris, Siberian tiger (2013) Panthera tigris tigris, Bengal tiger (2013) Panthera uncia, snow leopard (2013) Prionailurus bengalensis, leopard cat (2016) Family Canidae Canis familiaris, dog (2005) Canis lupus lupus, wolf (2017). Lycaon pictus, african wild dog (2018) Family Ursidae Ailuropoda melanoleuca, giant panda (2010) Ursus arctos ssp. horribilis, Grizzly bear (2018) Ursus americanus, American black bear (2019) Ursus maritimus, Polar bear (2014) Family Odobenidae Odobenus rosmarus, walrus (2015) Family Phocidae Pusa sibirica, Baikal seal (2024) Pusa caspica, Caspian seal (2024) Phoca vitulina, Harbor seal (2024) Pusa hispida, Ringed seal (2024) Family Mustelidae Enhydra lutris kenyoni, sea otter (2017) Mustela erminea, stoat (2018) Mustela furo, ferret (2014) Pteronura brasiliensis, giant otter (2019) Order Chiroptera Family Megadermatidae Megaderma lyra, greater false vampire bat (2013) Family Mormoopidae Pteronotus parnellii, Parnell's mustached bat (2013) Family Pteropodidae Pteropus vampyrus, fruit bat (2012) Eidolon helvum, Old World fruit bat (2013) Family Rhinolophidae Rhinolophus ferrumequinum, greater horseshoe bat (2013) Family Vespertilionidae Myotis lucifugus, little brown bat (2010) Myotis mystacinus, whiskered bat (2024) Family Phyllostomidae Leptonycteris yerbabuenae, long nosed bat (2020) Leptonycteris nivalis, greater long nosed bat (2020) Musonycteris harrisoni, banana bat (2020) Artibeus jamaicensis, Jamaican fruit bat (2020) Macrotus waterhousii, Waterhouse's leaf-nosed bat (2020 Order Erinaceomorpha, Family Erinaceidae Erinaceus europaeus, western European hedgehog () Order Eulipotyphla, Family Solenodontidae Solenodon parodoxus, Hispaniolan solenodon (2018) Order Perissodactyla (odd-toed ungulates) Family Equidae Equus caballus, horse (2009 2018)
==== Shoulder disorders ==== A 2014 Cochrane review found insufficient evidence to determine whether electrotherapy was better than exercise at treating adhesive capsulitis. As of 2004, there is insufficient evidence to draw conclusions about any intervention for rotator cuff pathology, including electrotherapy; furthermore, methodological problems precluded drawing conclusions about the efficacy of any rehabilitation method for impingement syndrome.
Sources: en.wikipedia.org
Leslie Harold Collier (9 February 1921 – 14 March 2011) was a scientist responsible for developing a freeze-drying method to produce a more heat stable smallpox vaccine in the late 1940s. Collier added a key component, peptone, a soluble protein, to the process. This protected the virus, enabling the production of a heat-stable vaccine in powdered form. Previously, smallpox vaccines would become ineffective after 1–2 days at ambient temperature. The development of his vaccine production method played a large role in enabling the World Health Organization to initiate its global smallpox eradication campaign in 1967.
While the Cro-Magnons are usually assumed to have generally practised sexual division of labour with men hunting and women gathering such as in the preponderance of recent hunter-gatherer societies, it is unclear to what extent this may be applied to Neanderthals. Both Neanderthal men and women have similar traumatic injury patterns, which might imply that both sexes were involved in hunting. Dental wearing patterns among Neanderthals, on the other hand, could indicate men and women typically carried different items with their mouths, though these may not have been related to subsistence tasks. The women at El Sidrón Cave, Spain, may have been eating more seeds and nuts than the men. The lack of distinctive task specialization in Neanderthals has usually been linked to their small population and group size, falling short of the demographic threshold where task specialization becomes feasible — which may also explain the comparative simplicity of Neanderthal material culture.
Delta-beta thalassemia is a rare form of thalassemia in which there is a reduced production of hemoglobin subunit delta and hemoglobin subunit beta and raised levels of hemoglobin subunit gamma. It is an autosomal recessive disorder.
=== Intestinal dialysis === In healthy humans, the intestines both remove uremic toxins (urea, creatine, uric acid) from blood and add uremic toxins (indoxyl sulfate, ammonia, etc.) to blood. More uremic toxins are excreted through the gut (as feces) than through the kidneys (as urine). This exchange of substances is enabled by the massive surface area of the intestinal capillary network and intestinal mucus, together serving as a large semipermeable membrane. In patients with kidney failure, the intestines receive a larger influx of uremic toxins due to a higher concentration in blood, but this does not automatically translate to a benefit in reducing blood toxin levels as gut bacteria use these toxins as food, producing more toxins in the process. The goal of intestinal dialysis is to maximize the removal of uremic toxins into the intestines while minimizing the production of new toxin molecules in the intestines. It serves as a more conservative renal replacement therapy for those unable to tolerate conventional dialysis. There are a few forms of intestinal dialysis:
Many described the separation from family members as excruciating, with some children being unable to talk to their parents, living with relatives in Gaza or having to monitor and parent younger siblings while their parents care for their injured siblings. On 16 August 2025, the U.S. State Department announced that it had suspended the issuance of visitor visas to people from the Gaza Strip, including children who require urgent medical care. In January–April 2024, medical evacuations for children from Gaza averaged about 296 per month; by late 2024 the rate had fallen to under one per day. In October 2024, UNICEF said children were dying not only from the violence itself but also because survivors were often unable to leave Gaza for urgent, life-saving treatment. By July/September 2025, an estimated 2,500-4,500 of critically wounded children are waiting for permits to be evacuated for care.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
The mass difference from the linker is large enough for routine detection by mass spectrometry. The unconjugated form gives a single sharp signal at its expected weight. Material that has already reacted with albumin shows a much higher mass and a broadened chromatographic peak.